Skip to main content
Erschienen in: Virchows Archiv 1/2015

01.07.2015 | Original Article

Toll-like receptor 9 expression in the natural history of Barrett mucosa

verfasst von: Heikki Huhta, Olli Helminen, Joonas H. Kauppila, Heikki Takala, Kalervo Metsikkö, Petri Lehenkari, Juha Saarnio, Tuomo Karttunen

Erschienen in: Virchows Archiv | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Increased expression of TLR9 in esophageal adenocarcinoma and squamous cell carcinoma correlates with poor prognosis. We have explored the expression and suspected that TLR9 activation might contribute to pathogenesis in esophageal columnar metaplasia-dysplasia-neoplasia sequence, and hence, we have studied the usefulness of TLR9 as a marker for dysplasia. We have determined the expression of TLR9 in specimens with normal esophagus (n = 89), gastric (n = 71), or intestinal metaplasia (n = 56) without dysplasia, and low-grade (n = 51) or high-grade dysplasia (n = 40), and esophageal adenocarcinoma (n = 88). We observed linearly increasing TLR9 expression in specimens to be associated with change from normal epithelium to columnar metaplasia and further to dysplasia. ROC curve analysis showed clinically irrelevant sensitivity of 71 % and specificity of 67 % for TLR9 intensity in detection of low-grade dysplasia. Membrane-associated TLR9 expression detected by immunohistochemistry and immunofluorescence was predominantly associated with foveolar-type dysplasia as detected by HE staining (p = 0.015). TLR9 is expressed in Barrett’s esophagus, and dissolution of TLR9 staining increases from nondysplastic epithelium to dysplastic. TLR9 may serve as a new way of recognizing the histopathological origin of dysplasia (adenomatous vs foveolar) with observed subcellular pattern of TLR9.
Literatur
1.
Zurück zum Zitat Holscher AH, Vallbohmer D, Bollschweiler E (2008) EarlyBarrett'scarcinoma of the esophagus. Ann Thorac Cardiovasc Surg 14:347–354PubMed Holscher AH, Vallbohmer D, Bollschweiler E (2008) EarlyBarrett'scarcinoma of the esophagus. Ann Thorac Cardiovasc Surg 14:347–354PubMed
3.
Zurück zum Zitat Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ (2010) Risk of esophagealadenocarcinoma and mortality in patients with Barrett'sesophagus: a systematicreview and meta-analysis. Clin Gastroenterol Hepatol 8:235–244 Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ (2010) Risk of esophagealadenocarcinoma and mortality in patients with Barrett'sesophagus: a systematicreview and meta-analysis. Clin Gastroenterol Hepatol 8:235–244
4.
Zurück zum Zitat Badreddine RJ, Wang KK (2010) Barrettesophagus: an update. Nat Rev Gastroenterol Hepatol 7:369–378PubMedCrossRef Badreddine RJ, Wang KK (2010) Barrettesophagus: an update. Nat Rev Gastroenterol Hepatol 7:369–378PubMedCrossRef
5.
Zurück zum Zitat Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinomaamongpatients with Barrett'sesophagus. N Engl J Med 365:1375–1383PubMedCrossRef Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinomaamongpatients with Barrett'sesophagus. N Engl J Med 365:1375–1383PubMedCrossRef
6.
Zurück zum Zitat Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR (2000) The diagnosis of low-gradedysplasia in Barrett'sesophagus and itsimplications for disease progression. Am J Gastroenterol 95:3383–3387PubMedCrossRef Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR (2000) The diagnosis of low-gradedysplasia in Barrett'sesophagus and itsimplications for disease progression. Am J Gastroenterol 95:3383–3387PubMedCrossRef
7.
Zurück zum Zitat Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD (2007) Extent of low-gradedysplasia is a riskfactor for the development of esophagealadenocarcinoma in Barrett'sesophagus. Am J Gastroenterol 102:483–493 Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD (2007) Extent of low-gradedysplasia is a riskfactor for the development of esophagealadenocarcinoma in Barrett'sesophagus. Am J Gastroenterol 102:483–493
8.
Zurück zum Zitat American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011) American Gastroenterological Association medical position statement on the management of Barrett'sesophagus. Gastroenterology 140:1084–1091CrossRef American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011) American Gastroenterological Association medical position statement on the management of Barrett'sesophagus. Gastroenterology 140:1084–1091CrossRef
9.
Zurück zum Zitat Abreu MT, Fukata M, Arditi M (2005) TLR signaling in the gut in health and disease. J Immunol 174:4453–4460PubMedCrossRef Abreu MT, Fukata M, Arditi M (2005) TLR signaling in the gut in health and disease. J Immunol 174:4453–4460PubMedCrossRef
10.
11.
Zurück zum Zitat Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM, Albini A (2010) The tumormicroenvironment of colorectalcancer: stromal TLR-4 expression as a potentialprognosticmarker. J Transl Med 8:112 Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM, Albini A (2010) The tumormicroenvironment of colorectalcancer: stromal TLR-4 expression as a potentialprognosticmarker. J Transl Med 8:112
12.
Zurück zum Zitat Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, Gonzalez JM, Escaff S, Vizoso FJ (2011) Study of TLR3, TLR4, and TLR9 in prostatecarcinomas and their association with biochemicalrecurrence. Cancer Immunol Immunother 60:217–226PubMedCrossRef Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, Gonzalez JM, Escaff S, Vizoso FJ (2011) Study of TLR3, TLR4, and TLR9 in prostatecarcinomas and their association with biochemicalrecurrence. Cancer Immunol Immunother 60:217–226PubMedCrossRef
13.
Zurück zum Zitat Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) IncreasedToll-likereceptor 9 expressionindicatesadverseprognosis in oesophagealadenocarcinoma. Histopathology 59:643–649PubMedCrossRef Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) IncreasedToll-likereceptor 9 expressionindicatesadverseprognosis in oesophagealadenocarcinoma. Histopathology 59:643–649PubMedCrossRef
14.
Zurück zum Zitat Kauppila JH, Mattila AE, Karttunen TJ, Salo T (2013) Toll-likereceptor 5 (TLR5) expression is a novelpredictivemarker for recurrence and survival in squamouscellcarcinoma of the tongue. Br J Cancer 108:638–643PubMedCentralPubMedCrossRef Kauppila JH, Mattila AE, Karttunen TJ, Salo T (2013) Toll-likereceptor 5 (TLR5) expression is a novelpredictivemarker for recurrence and survival in squamouscellcarcinoma of the tongue. Br J Cancer 108:638–643PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS (2008) Toll-likereceptor 9 mediatesCpGoligonucleotide-inducedcellularinvasion. Mol Cancer Res 6:1534–1543PubMedCrossRef Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS (2008) Toll-likereceptor 9 mediatesCpGoligonucleotide-inducedcellularinvasion. Mol Cancer Res 6:1534–1543PubMedCrossRef
17.
Zurück zum Zitat Zhang Y, Wang Q, Ma A, Li Y, Li R, Wang Y (2014) Functionalexpression of TLR9 in esophagealcancer. Oncol Rep 31:2298–2304PubMed Zhang Y, Wang Q, Ma A, Li Y, Li R, Wang Y (2014) Functionalexpression of TLR9 in esophagealcancer. Oncol Rep 31:2298–2304PubMed
18.
Zurück zum Zitat Kauppila JH, Karttunen TJ, Saarnio J, Nyberg P, Salo T, Graves DE, Lehenkari PP, Selander KS (2013) Short DNA sequences and bacterial DNA induceesophageal, gastric, and colorectalcancercellinvasion. APMIS 121:511–522PubMedCrossRef Kauppila JH, Karttunen TJ, Saarnio J, Nyberg P, Salo T, Graves DE, Lehenkari PP, Selander KS (2013) Short DNA sequences and bacterial DNA induceesophageal, gastric, and colorectalcancercellinvasion. APMIS 121:511–522PubMedCrossRef
19.
Zurück zum Zitat Kotrashetti VS, Nayak R, Bhat K, Hosmani J, Somannavar P (2013) Immunohistochemicalexpression of TLR4 and TLR9 in variousgrades of oralepithelialdysplasia and squamouscellcarcinoma, and theirroles in tumor progression: a pilotstudy. Biotech Histochem 88:311–322PubMedCrossRef Kotrashetti VS, Nayak R, Bhat K, Hosmani J, Somannavar P (2013) Immunohistochemicalexpression of TLR4 and TLR9 in variousgrades of oralepithelialdysplasia and squamouscellcarcinoma, and theirroles in tumor progression: a pilotstudy. Biotech Histochem 88:311–322PubMedCrossRef
20.
Zurück zum Zitat Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Toll-likereceptor 9 is a novelbiomarker for esophagealsquamouscelldysplasia and squamouscellcarcinoma progression. J Innate Immun 3:631–638PubMedCrossRef Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Toll-likereceptor 9 is a novelbiomarker for esophagealsquamouscelldysplasia and squamouscellcarcinoma progression. J Innate Immun 3:631–638PubMedCrossRef
21.
Zurück zum Zitat Elliot F, Ross-Innes CS, Eldridge MD, Fitzgerald RC (2014) The toll-likereceptorpathway is recurrentlymutated in oesophagealadenocarcinoma. Gut 63:A8, OralpresentationCrossRef Elliot F, Ross-Innes CS, Eldridge MD, Fitzgerald RC (2014) The toll-likereceptorpathway is recurrentlymutated in oesophagealadenocarcinoma. Gut 63:A8, OralpresentationCrossRef
22.
Zurück zum Zitat Helminen O, Huhta H, Takala H, Lehenkari PP, Saarnio J, Kauppila JH, Karttunen TJ (2014) IncreasedToll-likereceptor 5 expressionindicatesesophagealcolumnardysplasia. Virchows Arch 464:11–18PubMedCrossRef Helminen O, Huhta H, Takala H, Lehenkari PP, Saarnio J, Kauppila JH, Karttunen TJ (2014) IncreasedToll-likereceptor 5 expressionindicatesesophagealcolumnardysplasia. Virchows Arch 464:11–18PubMedCrossRef
23.
Zurück zum Zitat Odze RD (2009) Barrettesophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol 6:478–490PubMedCrossRef Odze RD (2009) Barrettesophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol 6:478–490PubMedCrossRef
24.
Zurück zum Zitat Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H (1988) Observervariation in the diagnosis of dysplasia in Barrett'sesophagus. Hum Pathol 19:166–178PubMedCrossRef Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H (1988) Observervariation in the diagnosis of dysplasia in Barrett'sesophagus. Hum Pathol 19:166–178PubMedCrossRef
25.
Zurück zum Zitat Brown IS, Whiteman DC, Lauwers GY (2010) Foveolartypedysplasia in Barrettesophagus. Mod Pathol 23:834–843PubMedCrossRef Brown IS, Whiteman DC, Lauwers GY (2010) Foveolartypedysplasia in Barrettesophagus. Mod Pathol 23:834–843PubMedCrossRef
26.
Zurück zum Zitat Khor TS, Alfaro EE, Ooi EM, Li Y, Srivastava A, Fujita H, Park Y, Kumarasinghe MP, Lauwers GY (2012) Divergentexpression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosaladenocarcinomas with intestinal and foveolarmorphology: is thisevidence of distinctgastric and intestinalpathways to carcinogenesis in BarrettEsophagus? Am J Surg Pathol 36:331–342PubMedCrossRef Khor TS, Alfaro EE, Ooi EM, Li Y, Srivastava A, Fujita H, Park Y, Kumarasinghe MP, Lauwers GY (2012) Divergentexpression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosaladenocarcinomas with intestinal and foveolarmorphology: is thisevidence of distinctgastric and intestinalpathways to carcinogenesis in BarrettEsophagus? Am J Surg Pathol 36:331–342PubMedCrossRef
27.
Zurück zum Zitat Odze RD (2011) What the gastroenterologistneeds to knowabout the histology of Barrett'sesophagus. Curr Opin Gastroenterol 27:389–396PubMedCrossRef Odze RD (2011) What the gastroenterologistneeds to knowabout the histology of Barrett'sesophagus. Curr Opin Gastroenterol 27:389–396PubMedCrossRef
28.
Zurück zum Zitat Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M (2005) Toll-likereceptors TLR4, TLR5 and TLR9 on gastriccarcinomacells: an implication for interaction with Helicobacterpylori. Int J Med Microbiol 295:179–185PubMedCrossRef Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M (2005) Toll-likereceptors TLR4, TLR5 and TLR9 on gastriccarcinomacells: an implication for interaction with Helicobacterpylori. Int J Med Microbiol 295:179–185PubMedCrossRef
29.
Zurück zum Zitat Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller-Hermelink HK, Eck M (2004) Expression and subcellulardistribution of toll-likereceptors TLR4, TLR5 and TLR9 on the gastricepithelium in Helicobacterpyloriinfection. Clin Exp Immunol 136:521–526PubMedCentralPubMedCrossRef Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller-Hermelink HK, Eck M (2004) Expression and subcellulardistribution of toll-likereceptors TLR4, TLR5 and TLR9 on the gastricepithelium in Helicobacterpyloriinfection. Clin Exp Immunol 136:521–526PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Kusagawa S, Ogura S, Tanaka J, Yoneda M, Yamamoto N, Okano H, Takei Y, Ito M, Kasai C, Inoue H, Takase K (2013) The expression and function of Toll-likereceptors 3 and 9 in humancoloncarcinoma. Oncol Rep 29:1737–1743PubMed Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Kusagawa S, Ogura S, Tanaka J, Yoneda M, Yamamoto N, Okano H, Takei Y, Ito M, Kasai C, Inoue H, Takase K (2013) The expression and function of Toll-likereceptors 3 and 9 in humancoloncarcinoma. Oncol Rep 29:1737–1743PubMed
31.
Zurück zum Zitat Mantani Y, Kamezaki A, Udayanga KG, Takahara EI, Qi WM, Kawano J, Yokoyama T, Hoshi N, Kitagawa H (2011) Sitedifferences of Toll-likereceptorexpression in the mucousepithelium of ratsmallintestine. Histol Histopathol 26:1295–1303PubMed Mantani Y, Kamezaki A, Udayanga KG, Takahara EI, Qi WM, Kawano J, Yokoyama T, Hoshi N, Kitagawa H (2011) Sitedifferences of Toll-likereceptorexpression in the mucousepithelium of ratsmallintestine. Histol Histopathol 26:1295–1303PubMed
32.
Zurück zum Zitat Nicholson A, Jankowski J (2009) Editorial: One smallstep for metaplasia, butonegiantleap for biomarkers is needed. Am J Gastroenterol 104:2681–2683PubMedCrossRef Nicholson A, Jankowski J (2009) Editorial: One smallstep for metaplasia, butonegiantleap for biomarkers is needed. Am J Gastroenterol 104:2681–2683PubMedCrossRef
33.
Zurück zum Zitat Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, Stoop HA, Walter L, Kuipers EJ, Spaander MC, Bruno MJ, ProBar-studygroup (2013) Aberrant p53 proteinexpression is associated with an increasedrisk of neoplastic progression in patients with Barrett'soesophagus. Gut 62:1676–1683PubMedCrossRef Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, Stoop HA, Walter L, Kuipers EJ, Spaander MC, Bruno MJ, ProBar-studygroup (2013) Aberrant p53 proteinexpression is associated with an increasedrisk of neoplastic progression in patients with Barrett'soesophagus. Gut 62:1676–1683PubMedCrossRef
34.
Zurück zum Zitat Kerkhof M, Steyerberg EW, Kusters JG, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD (2008) Aneuploidy and highexpression of p53 and Ki67 is associated with neoplastic progression in Barrettesophagus. Cancer Biomark 4:1–10PubMed Kerkhof M, Steyerberg EW, Kusters JG, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD (2008) Aneuploidy and highexpression of p53 and Ki67 is associated with neoplastic progression in Barrettesophagus. Cancer Biomark 4:1–10PubMed
35.
Zurück zum Zitat Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ (2009) Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett'sesophagus: a case-controlstudy. Am J Gastroenterol 104:2673–2680PubMedCrossRef Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ (2009) Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett'sesophagus: a case-controlstudy. Am J Gastroenterol 104:2673–2680PubMedCrossRef
36.
Zurück zum Zitat Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L (2003) Normalkeratinocytes express Toll-likereceptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronicplaque psoriasis. Br J Dermatol 148:670–679PubMedCrossRef Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L (2003) Normalkeratinocytes express Toll-likereceptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronicplaque psoriasis. Br J Dermatol 148:670–679PubMedCrossRef
37.
Zurück zum Zitat Nurmenniemi S, Kuvaja P, Lehtonen S, Tiuraniemi S, Alahuhta I, Mattila RK, Risteli J, Salo T, Selander KS, Nyberg P, Lehenkari P (2010) Toll-likereceptor 9 ligandsenhancemesenchymalstemcellinvasion and expression of matrix metalloprotease-13. Exp Cell Res 316:2676–2682PubMedCrossRef Nurmenniemi S, Kuvaja P, Lehtonen S, Tiuraniemi S, Alahuhta I, Mattila RK, Risteli J, Salo T, Selander KS, Nyberg P, Lehenkari P (2010) Toll-likereceptor 9 ligandsenhancemesenchymalstemcellinvasion and expression of matrix metalloprotease-13. Exp Cell Res 316:2676–2682PubMedCrossRef
38.
Zurück zum Zitat Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z (2009) Inflammation and intestinalmetaplasia of the distalesophagusareassociated with alterations in the microbiome. Gastroenterology 137:588–597PubMedCentralPubMedCrossRef Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z (2009) Inflammation and intestinalmetaplasia of the distalesophagusareassociated with alterations in the microbiome. Gastroenterology 137:588–597PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Yang L, Francois F, Pei Z (2012) Molecularpathways: pathogenesis and clinicalimplications of microbiomealteration in esophagitis and Barrettesophagus. Clin Cancer Res 18:2138–2144PubMedCentralPubMedCrossRef Yang L, Francois F, Pei Z (2012) Molecularpathways: pathogenesis and clinicalimplications of microbiomealteration in esophagitis and Barrettesophagus. Clin Cancer Res 18:2138–2144PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat De Nardo D, De Nardo CM, Nguyen T, Hamilton JA, Scholz GM (2009) Signalingcrosstalkduringsequential TLR4 and TLR9 activationamplifies the inflammatoryresponse of mousemacrophages. J Immunol 183:8110–8118PubMedCrossRef De Nardo D, De Nardo CM, Nguyen T, Hamilton JA, Scholz GM (2009) Signalingcrosstalkduringsequential TLR4 and TLR9 activationamplifies the inflammatoryresponse of mousemacrophages. J Immunol 183:8110–8118PubMedCrossRef
41.
Zurück zum Zitat Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, Kagnoff M, Eckmann L, Ben-Neriah Y, Raz E (2006) Maintenance of colonichomeostasisbydistinctiveapical TLR9 signalling in intestinalepithelialcells. Nat Cell Biol 8:1327–1336PubMedCrossRef Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, Kagnoff M, Eckmann L, Ben-Neriah Y, Raz E (2006) Maintenance of colonichomeostasisbydistinctiveapical TLR9 signalling in intestinalepithelialcells. Nat Cell Biol 8:1327–1336PubMedCrossRef
42.
Zurück zum Zitat de Kivit S, van Hoffen E, Korthagen N, Garssen J, Willemsen LE (2011) Apical TLR ligation of intestinalepithelialcellsdrives a Th1-polarized regulatoryorinflammatorytypeeffectorresponse in vitro. Immunobiology 216:518–527PubMedCrossRef de Kivit S, van Hoffen E, Korthagen N, Garssen J, Willemsen LE (2011) Apical TLR ligation of intestinalepithelialcellsdrives a Th1-polarized regulatoryorinflammatorytypeeffectorresponse in vitro. Immunobiology 216:518–527PubMedCrossRef
Metadaten
Titel
Toll-like receptor 9 expression in the natural history of Barrett mucosa
verfasst von
Heikki Huhta
Olli Helminen
Joonas H. Kauppila
Heikki Takala
Kalervo Metsikkö
Petri Lehenkari
Juha Saarnio
Tuomo Karttunen
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 1/2015
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-015-1770-3

Weitere Artikel der Ausgabe 1/2015

Virchows Archiv 1/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …